Sacituzumab Govitecan in cisplatin-ineligible metastatic urothelial cancer after CPI

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy

Authors: Daniel P. Petrylak, Scott T. Tagawa, Rohit K. Jain, Manojkumar Bupathi, Arjun Balar, Arash Rezazadeh Kalebasty, Saby George, Phillip Palmbos, Luke Nordquist, Nancy Davis,  Chethan Ramamurthy, Cora N. Sternberg, Yohann Loriot,  Neeraj Agarwal, Chandler Park,  Julia Tonelli,  Morganna Vance,  Huafeng Zhou and Petros Grivas.

Some authors of the article shared the following comments:

Petros Grivas shared on X:

“Excited to share our Journal of Clinical Oncology paper with Dan Petrylak, Scott Tagawa, Neeraj Agarwal, Cora Sternberg, Chandler Park, Rohit Jain et al. on SG alone s/p ICI: ORR 32%, mDOR 6 months, rapid responses, should give G-CSF as primary prophylaxis with SG in urothelial Ca! ”

Quoting Yüksel Ürün‘s post on X:

“TROPHY-U-01 Cohort 2:

Sacituzumab Govitecan achieved an ORR of 32% in cisplatin-ineligible metastatic urothelial cancer. Median PFS was 5.6 months. Main toxicities: neutropenia (34%), anemia (24%), and diarrhea (16%). ”

Quoting Chandler Park‘s post on LinkedIn:

Grateful to share our bladder cancer paper just published this week in Journal of Clinical Oncology
with Daniel Petrylak, Scott Tagawa, Rohit Jain, Neeraj Agarwal, Cora Sternberg, Manoj Bupathi, Saby George, Luke Nordquist, Nancy Davis and Petros Grivas .

For patients with Bladder Cancer, Sacituzumab Govitecan (SG) monotherapy demonstrated a relatively HIGH Objective Response Rate w/rapid responses; this was feasible with a manageable toxicity profile in cisplatin-ineligible patients who had progression after CPI therapy.

Key is prophylactic G-CSF for all patients receiving SG!

ORR was 32% (95% CI, 17.5 to 48.7), CBR 42% (95% CI, 26.3 to 59.2), median DOR 5.6 months (95% CI, 2.8 to 13.3), median PFS 5.6 months (95% CI, 4.1 to 8.3), and median overall survival 13.5 months

Source: Petros Grivas/X, Yüksel Ürün/X  and Chandler Park/LinkedIn

Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018.

With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.

Chandler Park, MD, FACP is an haematologist oncologist, medical journalist, and clinical researcher. He is the Advisory Dean and Clinical Professor at University of Louisville School of Medicine. He is the Kentucky Physician Representative of the ASCO State Executive Council. He is also the Medical Oncology Board Examiner at  American Board of Internal Medicine.